Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and re
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-14 7:53 AM EDT | Rhelion Life Sciences Corp.
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration (FDA).
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-14 7:00 AM EDT | Phio Pharmaceuticals Corp.
Beckett's Announces Results of Its 2026 Annual and Special Meeting of Shareholders and the Granting of Stock Options
Ontario and Los Angeles, California--(Newsfile Corp. - September 14, 2026) - Beckett's Inc. (CSE: BKTS) ("Beckett's" or the "Company") announces that all items of business were approved by shareholders at the Company's Annual and Special Meeting of shareholders held on September 10, 2026. All five proposed director nominees were elected by shareholders. Shareholders also voted in favour of the re-appointment of Zeifmans LLP as the Company's auditor for the ensuing
Food / Beverages, Cannabis, Health
2026-09-14 7:00 AM EDT | Becketts Inc.
Promino Holds Rejuvenate Muscle Health(TM) U.S. Retail Pricing as Whey Protein Costs Remain at Record Levels
WPC80 whey pricing has increased more than fivefold since 2023, reaching approximately US$14.50/lb in 2026 Rejuvenate remains US$24.99 for 14 servings and US$39.99 for 30 servings at U.S. retail — as much as 40% lower per serving than a current leading 2-lb whey benchmark Published human research supports the ability of a low-dose leucine-rich essential amino acid formulation to stimulate muscle protein synthesis compa
Food / Beverages, Sports, Health
2026-09-14 7:00 AM EDT | Promino Nutritional Sciences, Inc.
BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-1
Biotechnology, Pharmaceuticals, Health
2026-09-14 7:00 AM EDT | BioHarvest Sciences Inc.
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has filed a final short form prospectus (the "Final Prospectus") with the securities regulatory authorities in the provinces of British
2026-09-11 7:45 PM EDT | BetterLife Pharma Inc.
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte Ne
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-11 9:00 AM EDT | Phio Pharmaceuticals Corp.
Naia Relief Announces Conditional Approval for Listing on the TSX Venture Exchange and Commencement of Trading
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - Naia Relief Inc. (the "Company" or "Naia Relief") is pleased to announce that it has received conditional approval of the TSX Venture Exchange ("TSXV") to list its common shares on the TSXV. The Company's common shares will commence trading on the TSXV under the symbol "NAIA", effective market open on September 15, 2026. In addition, further to the Company's press release of September 8, 2026, an a
2026-09-11 7:00 AM EDT | Naia Relief Inc.
Psyched Wellness Announces Secured Term Loan
Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. (together the "Lenders") for an aggregat
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-09-10 4:15 PM EDT | Psyched Wellness Ltd.
DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctivitis
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive final results from its clinical study conducted with AlyaTec for TeaRx™ Red Eye further to the Company's press releases dated December 2, 2025, February 26, 2026, and July 9, 2026. The final results were obtained and analysed from 93 tear sa
2026-09-10 8:30 AM EDT | DiagnosTear Technologies Inc.
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic se
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-10 7:55 AM EDT | Rhelion Life Sciences Corp.
MD Hyperbaric Appoints Renowned Hyperbaric Researcher Dr. Amir Hadanny as Chief Medical Officer
New York, New York--(Newsfile Corp. - September 9, 2026) - MD Hyperbaric, one of the fastest-growing hyperbaric oxygen therapy (HBOT) networks in the United States, announced the appointment of Amir Hadanny, MD, as Chief Medical Officer. Dr. Hadanny is a neurosurgeon and hyperbaric physician and one of the most published clinical researchers in hyperbaric medicine, with more than 80 peer-reviewed publications. In this role,
Healthcare and Hospitals, Health
2026-09-09 9:00 AM EDT | MD Hyperbaric
LevelJump Announces Management Change
Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") wishes to announce the appointment of Gus Patel as the Company's interim Chief Financial Officer effective September 1, 2026, replacing Robert Landau. Gus Patel is a finance executive, tax practitioner and licensed public accountant with more than 15 years of experience across public companies, private enterprises and professiona
Healthcare and Hospitals, Health
2026-09-09 8:37 AM EDT | LevelJump Healthcare Corp.
QScreen AI Announces Closing of Final Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the final tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the final tranche of its previously announced non-
2026-09-09 6:15 AM EDT | QScreen AI Inc.
WELL Health Announces Planned CFO Transition; Evelyn Sutherland Appointed Chief Financial Officer
WELL has appointed Evelyn Sutherland as Chief Financial Officer, effective September 21, 2026. Ms. Sutherland brings more than 20 years of senior financial leadership experience, including CFO roles at Staples Canada, Enercare Inc., KEYreit, and United Purchasing Group of Canada (Yum! Brands). Ms. Sutherland has served on the Board of WELL's subsidiary, WELLSTAR, over the past year and brings direct knowledge of the Company's strategy, governance an
Technology, Computer Software, Healthcare and Hospitals, Health
2026-09-09 6:00 AM EDT | WELL Health Technologies Corp.
Naia Relief Announces Closing of Reverse Takeover Transaction
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - Naia Relief Inc. (formerly, 1329308 B.C. Ltd.) (the "Company") announces that, further to its press releases dated October 3, 2025, July 6, 2026, July 30, 2026, August 19, 2026 and September 1, 2026, it has completed its previously announced reverse takeover transaction (the "Transaction") pursuant to which the Company acquired all of the issued and outstanding securities of Relief AI Inc. ("Relief AI").
2026-09-08 5:40 PM EDT | Naia Relief Inc.
Nasdaq Shareholder Requirements Just Verified By Adia Med
Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes: At least 300 round-lot holders; A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; and Adia Med has just verified that it currently has 361 round-lot holders, or
Healthcare and Hospitals, Health
2026-09-08 8:00 AM EDT | Adia Med Inc.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund The study is the first trial of PEX010 in a movement disorder and, to the Company's kno
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-08 7:52 AM EDT | Rhelion Life Sciences Corp.
Altrova Health Signs Exclusive U.S. Distribution Agreement to Launch Its Detection and Wellness Portfolio Across the United States
Toronto, Ontario--(Newsfile Corp. - September 8, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to announce that it has entered into an exclusive distribution agreement (the "Distribution Agreement") with Reliability Funding LLC ("Reliability" or the "Distributor") appointing Reliability as the Company's exclusive sales agent and distributor for its product portfolio across the entire United S
2026-09-08 7:07 AM EDT | Altrova Health Inc.
WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents
WELLTRUST™, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. HEALWELL's DARWEN™ AI platform is used to connect WELLTRUST™ patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Orga
Technology, Computer Software, Healthcare and Hospitals, Health
2026-09-08 6:30 AM EDT | WELL Health Technologies Corp.